Cargando…
Droplet digital PCR for the quantification of Alu methylation status in hematological malignancies
BACKGROUND: Alu repeats, belonging to the Short Interspersed Repetitive Elements (SINEs) class, contain about 25% of CpG sites in the human genome. Alu sequences lie in gene-rich regions, so their methylation is an important transcriptional regulation mechanism. Aberrant Alu methylation has been ass...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6303857/ https://www.ncbi.nlm.nih.gov/pubmed/30579366 http://dx.doi.org/10.1186/s13000-018-0777-x |
_version_ | 1783382242272215040 |
---|---|
author | Orsini, Paola Impera, Luciana Parciante, Elisa Cumbo, Cosimo Minervini, Crescenzio F. Minervini, Angela Zagaria, Antonella Anelli, Luisa Coccaro, Nicoletta Casieri, Paola Tota, Giuseppina Brunetti, Claudia Ricco, Alessandra Carluccio, Paola Specchia, Giorgina Albano, Francesco |
author_facet | Orsini, Paola Impera, Luciana Parciante, Elisa Cumbo, Cosimo Minervini, Crescenzio F. Minervini, Angela Zagaria, Antonella Anelli, Luisa Coccaro, Nicoletta Casieri, Paola Tota, Giuseppina Brunetti, Claudia Ricco, Alessandra Carluccio, Paola Specchia, Giorgina Albano, Francesco |
author_sort | Orsini, Paola |
collection | PubMed |
description | BACKGROUND: Alu repeats, belonging to the Short Interspersed Repetitive Elements (SINEs) class, contain about 25% of CpG sites in the human genome. Alu sequences lie in gene-rich regions, so their methylation is an important transcriptional regulation mechanism. Aberrant Alu methylation has been associated with tumor aggressiveness, and also previously discussed in hematological malignancies, by applying different approaches. Moreover, today different techniques designed to measure global DNA methylation are focused on the methylation level of specific repeat elements. In this work we propose a new method of investigating Alu differential methylation, based on droplet digital PCR (ddPCR) technology. METHODS: Forty-six patients with hematological neoplasms were included in the study: 30 patients affected by chronic lymphocytic leukemia, 7 patients with myelodysplastic syndromes at intermediate/high risk, according with the International Prognostic Scoring System, and 9 patients with myelomonocytic leukemia. Ten healthy donors were included as controls. Acute promyelocytic leukemia-derived NB4 cell line, either untreated or treated with decitabine (DEC) hypomethylating agent, was also analyzed. DNA samples were investigated for Alu methylation level by digestion of genomic DNA with isoschizomers with differential sensitivity to DNA methylation, followed by ddPCR. RESULTS: Using ddPCR, a significant decrease of the global Alu methylation level in DNA extracted from NB4 cells treated with DEC, as compared to untreated cells, was observed. Moreover, comparing the global Alu methylation levels at diagnosis and after azacytidine (AZA) treatment in MDS patients, a statistically significant decrease of Alu sequences methylation after therapy as compared to diagnosis was evident. We also observed a significant decrease of the Alu methylation level in CLL patients compared to HD, and, finally, for CMML patients, a decrease of Alu sequences methylation was observed in patients harboring the SRSF2 hotspot gene mutation c.284C>D. CONCLUSIONS: In our work, we propose a method to investigate Alu differential methylation based on ddPCR technology. This assay introduces ddPCR as a more sensitive and immediate technique for Alu methylation analysis. To date, this is the first application of ddPCR to study DNA repetitive elements. This approach may be useful to profile patients affected by hematologic malignancies for diagnostic/prognostic purpose. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13000-018-0777-x) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6303857 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-63038572018-12-31 Droplet digital PCR for the quantification of Alu methylation status in hematological malignancies Orsini, Paola Impera, Luciana Parciante, Elisa Cumbo, Cosimo Minervini, Crescenzio F. Minervini, Angela Zagaria, Antonella Anelli, Luisa Coccaro, Nicoletta Casieri, Paola Tota, Giuseppina Brunetti, Claudia Ricco, Alessandra Carluccio, Paola Specchia, Giorgina Albano, Francesco Diagn Pathol Research BACKGROUND: Alu repeats, belonging to the Short Interspersed Repetitive Elements (SINEs) class, contain about 25% of CpG sites in the human genome. Alu sequences lie in gene-rich regions, so their methylation is an important transcriptional regulation mechanism. Aberrant Alu methylation has been associated with tumor aggressiveness, and also previously discussed in hematological malignancies, by applying different approaches. Moreover, today different techniques designed to measure global DNA methylation are focused on the methylation level of specific repeat elements. In this work we propose a new method of investigating Alu differential methylation, based on droplet digital PCR (ddPCR) technology. METHODS: Forty-six patients with hematological neoplasms were included in the study: 30 patients affected by chronic lymphocytic leukemia, 7 patients with myelodysplastic syndromes at intermediate/high risk, according with the International Prognostic Scoring System, and 9 patients with myelomonocytic leukemia. Ten healthy donors were included as controls. Acute promyelocytic leukemia-derived NB4 cell line, either untreated or treated with decitabine (DEC) hypomethylating agent, was also analyzed. DNA samples were investigated for Alu methylation level by digestion of genomic DNA with isoschizomers with differential sensitivity to DNA methylation, followed by ddPCR. RESULTS: Using ddPCR, a significant decrease of the global Alu methylation level in DNA extracted from NB4 cells treated with DEC, as compared to untreated cells, was observed. Moreover, comparing the global Alu methylation levels at diagnosis and after azacytidine (AZA) treatment in MDS patients, a statistically significant decrease of Alu sequences methylation after therapy as compared to diagnosis was evident. We also observed a significant decrease of the Alu methylation level in CLL patients compared to HD, and, finally, for CMML patients, a decrease of Alu sequences methylation was observed in patients harboring the SRSF2 hotspot gene mutation c.284C>D. CONCLUSIONS: In our work, we propose a method to investigate Alu differential methylation based on ddPCR technology. This assay introduces ddPCR as a more sensitive and immediate technique for Alu methylation analysis. To date, this is the first application of ddPCR to study DNA repetitive elements. This approach may be useful to profile patients affected by hematologic malignancies for diagnostic/prognostic purpose. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13000-018-0777-x) contains supplementary material, which is available to authorized users. BioMed Central 2018-12-22 /pmc/articles/PMC6303857/ /pubmed/30579366 http://dx.doi.org/10.1186/s13000-018-0777-x Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Orsini, Paola Impera, Luciana Parciante, Elisa Cumbo, Cosimo Minervini, Crescenzio F. Minervini, Angela Zagaria, Antonella Anelli, Luisa Coccaro, Nicoletta Casieri, Paola Tota, Giuseppina Brunetti, Claudia Ricco, Alessandra Carluccio, Paola Specchia, Giorgina Albano, Francesco Droplet digital PCR for the quantification of Alu methylation status in hematological malignancies |
title | Droplet digital PCR for the quantification of Alu methylation status in hematological malignancies |
title_full | Droplet digital PCR for the quantification of Alu methylation status in hematological malignancies |
title_fullStr | Droplet digital PCR for the quantification of Alu methylation status in hematological malignancies |
title_full_unstemmed | Droplet digital PCR for the quantification of Alu methylation status in hematological malignancies |
title_short | Droplet digital PCR for the quantification of Alu methylation status in hematological malignancies |
title_sort | droplet digital pcr for the quantification of alu methylation status in hematological malignancies |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6303857/ https://www.ncbi.nlm.nih.gov/pubmed/30579366 http://dx.doi.org/10.1186/s13000-018-0777-x |
work_keys_str_mv | AT orsinipaola dropletdigitalpcrforthequantificationofalumethylationstatusinhematologicalmalignancies AT imperaluciana dropletdigitalpcrforthequantificationofalumethylationstatusinhematologicalmalignancies AT parcianteelisa dropletdigitalpcrforthequantificationofalumethylationstatusinhematologicalmalignancies AT cumbocosimo dropletdigitalpcrforthequantificationofalumethylationstatusinhematologicalmalignancies AT minervinicrescenziof dropletdigitalpcrforthequantificationofalumethylationstatusinhematologicalmalignancies AT minerviniangela dropletdigitalpcrforthequantificationofalumethylationstatusinhematologicalmalignancies AT zagariaantonella dropletdigitalpcrforthequantificationofalumethylationstatusinhematologicalmalignancies AT anelliluisa dropletdigitalpcrforthequantificationofalumethylationstatusinhematologicalmalignancies AT coccaronicoletta dropletdigitalpcrforthequantificationofalumethylationstatusinhematologicalmalignancies AT casieripaola dropletdigitalpcrforthequantificationofalumethylationstatusinhematologicalmalignancies AT totagiuseppina dropletdigitalpcrforthequantificationofalumethylationstatusinhematologicalmalignancies AT brunetticlaudia dropletdigitalpcrforthequantificationofalumethylationstatusinhematologicalmalignancies AT riccoalessandra dropletdigitalpcrforthequantificationofalumethylationstatusinhematologicalmalignancies AT carlucciopaola dropletdigitalpcrforthequantificationofalumethylationstatusinhematologicalmalignancies AT specchiagiorgina dropletdigitalpcrforthequantificationofalumethylationstatusinhematologicalmalignancies AT albanofrancesco dropletdigitalpcrforthequantificationofalumethylationstatusinhematologicalmalignancies |